FENC · CIK 0001211583 · operating
Fennec Pharmaceuticals is a commercial-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company focuses on treatments for platinum-induced ototoxicity, a hearing loss condition that occurs as a side effect of platinum-based chemotherapy in pediatric cancer patients. Its primary product, PEDMARK (sodium thiosulfate), is formulated specifically to prevent this toxicity in children undergoing cancer treatment.
The company operates with a lean structure of 32 full-time employees and distributes PEDMARK through regional pediatric oncology specialists and medical science liaisons across the United States. PEDMARK represents the company's primary revenue stream, positioned within the pediatric oncology supportive care market. Fennec was incorporated in British Columbia in 1996 and rebranded from its former identity as Adherex Technologies in 2014 to reflect its strategic focus on rare and severe adverse effects in pediatric populations.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.02 | $-0.02 | +96.7% | |
| 2023 | $-0.60 | $-0.60 | +33.3% | |
| 2022 | $-0.90 | $-0.90 | -34.3% | |
| 2021 | $-0.67 | $-0.67 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | $-0.06 | $-0.06 | +72.7% | |
| 2014 | $-0.22 | $-0.22 | -466.7% | |
| 2013 | $0.06 | $0.06 | +128.6% | |
| 2012 | $-0.21 | $-0.21 | -210.5% | |
| 2011 | $0.19 | $0.20 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-26 | 0001558370-25-003710 | SEC ↗ |
| 2023-12-31 | 2024-03-29 | 0001558370-24-004383 | SEC ↗ |
| 2022-12-31 | 2023-03-29 | 0001558370-23-004948 | SEC ↗ |
| 2021-12-31 | 2022-02-28 | 0001558370-22-002334 | SEC ↗ |
| 2020-12-31 | 2021-03-30 | 0001104659-21-043756 | SEC ↗ |
| 2019-12-31 | 2020-02-14 | 0001104659-20-021132 | SEC ↗ |
| 2018-12-31 | 2019-03-15 | 0001144204-19-014220 | SEC ↗ |
| 2017-12-31 | 2018-03-28 | 0001144204-18-017571 | SEC ↗ |
| 2016-12-31 | 2017-03-29 | 0001144204-17-017299 | SEC ↗ |
| 2015-12-31 | 2016-03-28 | 0001144204-16-090604 | SEC ↗ |
| 2014-12-31 | 2015-03-31 | 0001144204-15-020272 | SEC ↗ |
| 2013-12-31 | 2014-03-31 | 0001144204-14-019399 | SEC ↗ |
| 2012-12-31 | 2013-04-01 | 0001144204-13-019057 | SEC ↗ |
| 2011-12-31 | 2012-03-27 | 0001144204-12-017470 | SEC ↗ |
| 2010-12-31 | 2011-03-31 | 0001144204-11-019011 | SEC ↗ |
| 2009-12-31 | 2010-03-31 | 0001116502-10-000268 | SEC ↗ |
| 2008-12-31 | 2009-03-30 | 0001193125-09-067881 | SEC ↗ |
| 2007-12-31 | 2008-03-28 | 0001193125-08-069303 | SEC ↗ |